Arcus's casdatifan data at R&D day lift hopes for a first-line kidney cancer role
- Arcus shares rose about 8% after updated casdatifan data at an R&D day; the HIF-2α inhibitor is in late-stage testing and works like Merck's Welireg.
- Analysts read the earlier-line tumor progression and survival findings as a step up in potency versus Welireg.
- One analyst argued it could become an all-line backbone in clear cell renal cell carcinoma.
💡 Points
The pitch is straightforward: a second-generation HIF-2α drug that beats the one drug in class on potency and moves earlier into treatment. The caveats are cross-trial comparison, immature data and a Merck incumbent with a head start. Casdatifan's value now hinges on the first-line Phase 3 designs rather than on these early-line numbers.
Arcus casdatifan R&D day update, TriGemX SPAC, Lilly–METiS (biotech news roundup) ↗